Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Análise de atributos sísmicos 3D para interpretação estrutural do campo de Poseidon, Bacia de Browse - NW da Austrália

Na indústria de hidrocarbonetos, a identificação de feições estruturais e/ou estratigráficas representa um papel primordial no fluxo de hidrocarbonetos e formação de trapas, de forma que a devida determinação de suas propriedades provoca impactos diretos sobre a avaliação do reservatório e/ou fonte. Uma importante ferramenta é a aplicação de atributos sísmicos, resultados de algoritmos matemáticos que envolvem o dado sísmico, cujo objetivo é ressaltar características do dado não perceptíveis no processo tradicional de processamento. A partir disso, este trabalho visa a análise de atributos sísmicos de similaridade, curvatura, mergulho e azimute calculados a partir de dados sísmicos 3D do Campo de Poseidon, Bacia de Browse, para identificação da geometria, das falhas e das feições do reservatório, com foco na Formação Plover. A Bacia de Browse, localizada ao NW da Austrália, possui seis fases tectonoestratigráficas, no qual se destaca a fase de extensão Jurássica e magmatismo, onde estão situados os arenitos da Fm. Plover (Jurássico Inferior a Médio), um dos reservatórios mais lateralmente extensos ao longo das sub-bacias Caswell e Barcoo, e o atual maior reservatório no principal campo da região, o de Torosa. Há uma correlação entre os aspectos tectonoestratigráficos da literatura e as configurações sísmicas observadas neste volume sísmico, tais como montiformas carbonáticas, paralela regular a subparalela, oblíqua sigmoidal, feições convexas e caótico/difuso. A relevância dos atributos para essa finalidade e também para as estruturas é feita a partir da interpretação com base em 7 atributos: similaridade, curvatura mais positiva, curvatura mais negativa, azimute instantâneo, curvatura de azimute de máximo mergulho, curvatura de mergulho e curvatura de máximo mergulho. Foi possível evidenciar o controle da tectônica rifte, caracterizada por falhas normais NE-SW, cegas e que apresentam disposição em graben em porções localizadas. De uma forma geral, destaca-se o atributo de similaridade, pela correspondência com a configuração das falhas e maior clareza para as feições sigmoidais, a curvatura de máximo mergulho e o azimute instantâneo, pela maior compreensão da distribuição espacial das falhas e direção de seus mergulhos principais e os atributos de curvatura, principalmente a positiva, para as feições de montiformas carbonáticasIn the hydrocarbon industry, the identification of structural and / or stratigraphic features plays a major role in the flow of hydrocarbons and formation of traps, so that the proper determination of their properties causes direct impacts on the evaluation of the reservoir and / or source. An important tool is the application of seismic attributes, results of mathematical algorithms that involve the seismic data, whose objective is to emphasize data characteristics not perceivable in the traditional process of processing. From this, this work aims at the analysis of seismic attributes of similarity, curvature, dip and azimuth calculated from 3D seismic data of the Poseidon Field, Browse Basin, to identify the geometry, faults and features of the reservoir, with focus on Plover Formation. The Browse Basin, located in NW Australia, has six tectonostratigraphic phases, in which the Jurassic and Magmatism extension phase stands out, bacaouse of the sandstones of the Plover Formation, one of the most laterally extensive reservoirs along the Caswell and Barcoo sub-basins, and the current largest reservoir in the region\u27s main field, Torosa. There is a correlation between the tectonostratigraphic aspects of the literature and the seismic configurations observed in this seismic volume, such as carbonate montiforms, regular parallel to subparallel, sigmoidal oblique, convex and chaotic / diffuse features. The relevance of the attributes for this purpose and also for the structures is made from the interpretation based on 7 attributes: similarity, most positive curvature, most negative curvature, instantaneous azimuth, azimuth in maximum dip, dip curvature and curvature of maximum dip. It was possible to demonstrate the control of rift tectonics, characterized by normal NE-SW faults, which are blind and have a graben disposition in localized portions. In general, the similarity attribute is highlighted, by the correspondence with the configuration of the faults and greater clarity for the sigmoidal features, the maximum dip curvature and the instantaneous azimuth, by the greater understanding of the spatial distribution of the faults and direction of their main dips and the attributes of curvature, mainly the positive, for the features of carbonate montiforma

Pore scale Investigation of the Use of Reactive Nanoparticles for In situ Remediation of Contaminated Groundwater Source

Nanoscale zero-valent iron (nZVI) particles have excellent capacity for in situ remediation of groundwater resources contaminated by a range of organic and inorganic contaminants. Chlorinated solvents are by far the most treated compounds. Studies at column, pilot, and field scales have reported successful decrease in contaminant concentration upon injection of nZVI suspensions in the contaminated zones. However, the field application is far from optimized, particularly for treatments at-or close to-the source, in the presence of residual nonaqueous liquid (NAPL). The knowledge gaps surrounding the processes that occur within the pores of the sediments hosting those contaminants at microscale limit our ability to design nanoremediation processes that are optimized at larger scales. This contribution provides a pore-scale picture of the nanoremediation process. Our results reveal how the distribution of the trapped contaminant evolves as a result of contaminant degradation and generation of gaseous products. We have used state-of-the-art four-dimensional (4D) imaging (time-resolved three-dimensional [3D]) experiments to understand the details of this degradation reaction at the micrometer scale. This contribution shows that the gas released (from the reduction reaction) remobilizes the trapped contaminant by overcoming the capillary forces. Our results show that the secondary sources of NAPL contaminations can be effectively treated by nZVI, not only by in situ degradation, but also through pore-scale remobilization (induced by the evolved gas phase). The produced gas reduces the water relative permeability to less than 1% and, therefore, significantly limits the extent of plume migration in the short term

X-ray computed tomography Dataset

Time-resolved X-ray computed dataset used to investigate the in situ remediation of contaminated groundwater by reactive nanoparticles